As Alzheimer's disease partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. Wednesday, that vision came into better focus as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback